title: Inhibitory effects of tricin derivative from Sasa albo-marginata on replication of human cytomegalovirus.
abstract: The anti-human cytomegalovirus (HCMV) activity of tricin (4',5,7-trihydroxy-3',5'-dimethoxyflavone), a derivative from Sasa albo-marginata, was studied in the human embryonic fibroblast cell line MRC-5. In a plaque assay, tricin and ganciclovir (GCV) showed concentration-dependent inhibitory properties from 0.05 to 3.6 μM and 0.01 to 1.0 μM, respectively. Tricin had no virucidal effects on cell-free HCMV. Treatment with tricin 1h before, or 1h or 3h after viral infection significantly suppressed HCMV replication. Moreover, tricin inhibited the expression of immediate early (IE) 2 mRNA and DNA polymerase (UL54) mRNA in HCMV-infected cells. Western blot analysis also demonstrated that tricin decreased the expression of IE antigen (especially IE2) and cyclooxygenase 2 (COX-2) expression in HCMV-infected cells. In the presence of tricin, prostaglandin E2 (PGE2) accumulation by HCMV infection was completely inhibited. These results suggest that tricin is a novel compound with potential COX inhibitor-dependent anti-HCMV activity.
authors: Department of Microbiology and Immunology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa 920-1181, Japan.
authors: Kazuhiko
authors: K
authors: Akuzawa
authors: Rie
authors: R
authors: Yamada
authors: Zhuan
authors: Z
authors: Li
authors: Ying
authors: Y
authors: Li
authors: Hidetaka
authors: H
authors: Sadanari
authors: Keiko
authors: K
authors: Matsubara
authors: Kunitomo
authors: K
authors: Watanabe
authors: Mamoru
authors: M
authors: Koketsu
authors: Yuuzo
authors: Y
authors: Tuchida
authors: Tsugiya
authors: T
authors: Murayama
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D015153:Blotting, Western; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000821:virology; D004279:DNA, Viral / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D004259:DNA-Directed DNA Polymerase / Q000096:biosynthesis; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects* / Q000821:virology; D005419:Flavonoids / Q000494:pharmacology*; D015774:Ganciclovir / Q000494:pharmacology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D019384:Nucleic Acid Synthesis Inhibitors; D020133:Reverse Transcriptase Polymerase Chain Reaction; D031787:Sasa / Q000737:chemistry; D014779:Virus Replication / Q000187:drug effects* / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D005419:Flavonoids; D017874:Immediate-Early Proteins; D019384:Nucleic Acid Synthesis Inhibitors; C017769:tricin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D004259:DNA-Directed DNA Polymerase; D015232:Dinoprostone; D015774:Ganciclovir